ArticleImmunologic research2025
PANoptosis-related genes in the prognosis and immune landscape of hepatocellular carcinoma.
Article in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.Cancer biology & medicine · 2025Pooled it
- Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma.Frontiers in immunology · 2026Article
- PANoptosis in hepatocellular carcinoma: Underlying mechanisms.World journal of hepatology · 2025Review
- The role of glucocorticoids in hepatocellular carcinoma through integrated bioinformatics analysis and experimental validation.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In hepatocellular carcinoma (HCC) individuals, the influence of numerous variables on the HCC prognosis has gained widespread recognition. Nevertheless, there remains a need for further elucidation regarding the underlying mechanism of PANoptosis-related genes (PRGs) on HCC. A consensus clustering approach, based on the TCGA-LIHC data, was used to identify specific subtypes linked to PANoptosis in this study. Next, a signature consisting of predictive differentially expressed genes for these subtypes was established using a least absolute shrinkage and selection operator (LASSO) regression analysis. Additionally, the reliability of the signature was confirmed through verification investigations using the data from the ICGC database and TCGA-LIHC. In the end, we developed a nomogram to enhance the clinical effectiveness of our prediction tool. PRG signature in this study has been highly related to the prognosis of individuals diagnosed with HCC, which was established with six genes. Also, this signature and clinicopathological features were put together to create a nomogram. Interestingly, the forecasting efficiency of this combination approach is better than other prediction models in the reported literature. In addition, an examination of the immunological surroundings indicates that the group with low risk exhibited elevated ESTIMATE score, ImmuneScores, and StromalScores. More, significant differences in infiltrating immune cells and the expression levels of immune-related genes were found between the two groups. In HCC patients, the PRG signature exhibits potential as a biomarker, offering a significant point of reference for tailoring individual therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.